210 related articles for article (PubMed ID: 27829380)
1. Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry.
Bergin K; Moore E; McQuilten Z; Wood E; Augustson B; Blacklock H; Ho J; Horvath N; King T; McNeil J; Mollee P; Quach H; Reid CM; Rosengarten B; Walker P; Spencer A
BMC Med Res Methodol; 2016 Nov; 16(1):151. PubMed ID: 27829380
[TBL] [Abstract][Full Text] [Related]
2. The establishment of a multiple myeloma clinical registry in the Asia-Pacific region: The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR).
Aoki N; Chen PY; Chen W; Chng WJ; Gan GG; Goh YT; Hou J; Huang J; Kim K; Lee JJ; Lu J; McQuilten ZK; Min CK; Moore E; Oliver L; Waters NA; Wellard C; Wood EM; Yeh SP; Spencer A;
BMC Med Res Methodol; 2024 May; 24(1):102. PubMed ID: 38698331
[TBL] [Abstract][Full Text] [Related]
3. Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry.
Lymphoma and Related Diseases Registry Investigators
BMC Med Res Methodol; 2022 Oct; 22(1):266. PubMed ID: 36217114
[TBL] [Abstract][Full Text] [Related]
4. Real-world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and related diseases registry.
Lim SL; Wellard C; Moore E; Harrison SJ; Hang Q; Ho J; Rajagopal R; Spencer A
Intern Med J; 2024 May; 54(5):773-778. PubMed ID: 38149340
[TBL] [Abstract][Full Text] [Related]
5. The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR).
Bergin K; Wellard C; Moore E; McQuilten Z; Blacklock H; Harrison SJ; Ho PJ; King T; Quach H; Mollee P; Walker P; Wood E; Spencer A;
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e510-e520. PubMed ID: 33785297
[TBL] [Abstract][Full Text] [Related]
6. Czech Registry of Monoclonal Gammopathies - Technical Solution, Data Collection and Visualisation.
Brozova L; Schwarz D; Snabl I; Kalina J; Pavlickova B; Komenda M; Jarkovský J; Němec P; Horinek D; Stefanikova Z; Pour L; Hájek R; Maisnar V
Klin Onkol; 2017; 30(Supplementum2):43-50. PubMed ID: 28903570
[TBL] [Abstract][Full Text] [Related]
7. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
8. Development of an International Prostate Cancer Outcomes Registry.
Evans SM; Nag N; Roder D; Brooks A; Millar JL; Moretti KL; Pryor D; Skala M; McNeil JJ
BJU Int; 2016 Apr; 117 Suppl 4():60-7. PubMed ID: 26877056
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal gammopathy of undetermined significance (MGUS)-31 year follow up of a community study.
Colls BM
Aust N Z J Med; 1999 Aug; 29(4):500-4. PubMed ID: 10868527
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease.
Srkalovic G; Cameron MG; Rybicki L; Deitcher SR; Kattke-Marchant K; Hussein MA
Cancer; 2004 Aug; 101(3):558-66. PubMed ID: 15274069
[TBL] [Abstract][Full Text] [Related]
11. Māori and Pacific Peoples With Multiple Myeloma in New Zealand are Younger and Have Inferior Survival Compared to Other Ethnicities: A Study From the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
Moore EM; Blacklock H; Wellard C; Spearing R; Merriman L; Poplar S; George A; Baker B; Chan H; McQuilten ZK; Wood EM; Spencer A;
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e762-e769. PubMed ID: 35501256
[TBL] [Abstract][Full Text] [Related]
12. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
13. Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
McQuilten Z; Wellard C; Moore E; Augustson B; Bergin K; Blacklock H; Harrison S; Ho PJ; King T; Quach H; Mollee P; Rosengarten B; Walker P; Wood E; Spencer A;
Br J Haematol; 2022 Sep; 198(5):830-837. PubMed ID: 35818641
[TBL] [Abstract][Full Text] [Related]
14. Improving outcomes for hospital patients with critical bleeding requiring massive transfusion: the Australian and New Zealand Massive Transfusion Registry study methodology.
Oldroyd JC; Venardos KM; Aoki NJ; Zatta AJ; McQuilten ZK; Phillips LE; Andrianopoulos N; Cooper DJ; Cameron PA; Isbister JP; Wood EM
BMC Res Notes; 2016 Oct; 9(1):457. PubMed ID: 27716381
[TBL] [Abstract][Full Text] [Related]
15. Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma.
Dutoit JC; Vanderkerken MA; Verstraete KL
Eur J Radiol; 2013 Sep; 82(9):1444-52. PubMed ID: 23726124
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology of Monoclonal Gammopathy of Undetermined Significance (MGUS): The experience from the specialized registry of hematologic malignancies of Basse-Normandie (France).
Cabrera Q; Macro M; Hebert B; Cornet E; Collignon A; Troussard X
Cancer Epidemiol; 2014 Aug; 38(4):354-6. PubMed ID: 24880205
[TBL] [Abstract][Full Text] [Related]
17. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
[TBL] [Abstract][Full Text] [Related]
18. Cancer statistics: everything you wanted to know about the cancer registry data but were too afraid to ask.
Giles GG; Thursfield V
ANZ J Surg; 2004 Nov; 74(11):931-4. PubMed ID: 15550077
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
20. Is the Durie and Salmon diagnostic classification system for plasma cell dyscrasias still the best choice? Application of three classification systems to a large population-based registry of paraproteinemia and multiple myeloma.
Ong F; Hermans J; Noordijk EM; Kluin-Nelemans JC
Ann Hematol; 1995 Jan; 70(1):19-24. PubMed ID: 7827202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
